ReviewCurrent rheumatology reports2013
Valvular heart disease in antiphospholipid syndrome.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 76 citations in OpenAlex.
- Nonbacterial Thrombotic Endocarditis and Mechanical Valve Thrombosis in a Patient with Antiphospholipid Syndrome.CASE (Philadelphia, Pa.) · 2026Article
- Antiphospholipid Syndrome: A Comprehensive Clinical Review.Journal of clinical medicine · 2025Review
- Diagnosis and management of antiphospholipid syndrome.Australian prescriber · 2024Review
- Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.Journal of clinical medicine · 2024Review
- Article
- Prevalence and adverse consequences of delayed diagnosis and misdiagnosis in thrombotic antiphospholipid syndrome. An observational cohort study and a review of the literature.Clinical rheumatology · 2023Review
- Suspected COVID-19 Immunization-Induced Probable Catastrophic Antiphospholipid Syndrome.Cureus · 2022Article
- Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.Clinical rheumatology · 2022Article
- Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.Frontiers in immunology · 2022Observational
- Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects.Paediatric drugs · 2022Review
- Anti-phospholipid syndrome and valvular pathology.Journal of echocardiography · 2021Article
- Combined brain/heart magnetic resonance imaging in antiphospholipid syndrome-two sides of the same coin.Clinical rheumatology · 2021Review
- Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome.Journal of clinical medicine · 2021Review
- Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management.Thrombosis research · 2021Review
- Cardiac Imaging of Aortic Valve Area From 34 287 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic Comorbidity With Multiple Disease Phenotypes.Circulation. Genomic and precision medicine · 2020Article
- Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.European journal of rheumatology · 2020Article
- Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report.Journal of cardiothoracic surgery · 2020Article
- Recurrent nonbacterial thrombotic endocarditis and stroke on anticoagulation.Journal of community hospital internal medicine perspectives · 2020Article
- Primary Antiphospholipid Antibody Syndrome Complicated with Cerebellar Hemorrhage and Aortic Dissection: A Case Report.The American journal of case reports · 2019Article
- A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.Immunologic research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart valve disease (HVD) is the most frequent cardiac manifestation in patients with antiphospholipid syndrome (APS), with prevalence of 30 %. The definition is based on the presence of thickening or vegetation of the valves (mainly mitral and aortic) as described by Libman and Sacks for patients with systemic lupus erythematosus (SLE). Transthoracic and/or transoesophageal echocardiography (TTE and TEE, respectively) enable early and accurate diagnosis and help avoid misdiagnosis as rheumatic valve disease. The presence of antiphospholipid antibodies (aPL) in SLE patients is associated with a threefold greater risk of HVD, confirming the crucial importance of these antibodies in the pathogenic process, leading to thrombotic manifestations on valves because of hypercoagulability. Natural history is characterized by worsening of HVD over time with an increased risk for stroke. APS patients undergoing valve-replacement surgery are at high risk of thrombotic and bleeding complications. Thus aPL-associated HVD has affects clinical management of APS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.